(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 15.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Ionis Pharmaceuticals's revenue in 2025 is $717,252,000.On average, 10 Wall Street analysts forecast IONS's revenue for 2025 to be $118,472,462,727, with the lowest IONS revenue forecast at $116,104,971,130, and the highest IONS revenue forecast at $125,162,715,454. On average, 10 Wall Street analysts forecast IONS's revenue for 2026 to be $134,972,327,361, with the lowest IONS revenue forecast at $98,809,151,841, and the highest IONS revenue forecast at $157,726,667,109.
In 2027, IONS is forecast to generate $181,134,832,435 in revenue, with the lowest revenue forecast at $64,300,275,996 and the highest revenue forecast at $216,615,533,739.